ResearcherHarvard UniversityActive in the last 2 years
Osama E. Rahma
Matched on ORCID iD 0000-0001-7302-5805; OpenAlex author ID A5080783554. Sources: ClinicalTrials.gov.
Their work
- Papers
- 12 (first author 0, last author 3)
- Trials
- 1
- Grants
- 0
- Labs led
- 0
- Collaborators
- 75
2013: 1 paper · 2014: none · 2015: 1 paper, 1 trial · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers
Papers 12
- Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
- PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
- Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
- Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Last author DOI 10.1136/jitc-2023-007586↗
- Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗
- CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/s1470-2045(20)30532-5↗
- Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
- Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment o… Co-author DOI 10.21037/jgo-21-197↗
- From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. Last author DOI 10.1186/s40425-016-0119-z↗
- Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Co-author DOI 10.1245/s10434-016-5116-4↗
- A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT… Last author DOI 10.1186/2051-1426-3-s2-p167↗
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Co-author DOI 10.1093/annonc/mdt166↗
Trials 1
Closest collaborators
The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Brian Matthew Wolpin · 5 shared papers, 2021–2024 · strength 0.65
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Andressa Dias Costa · 4 shared papers, 2021–2024 · strength 0.53
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Jonathan Andrew Nowak · 4 shared papers, 2021–2024 · strength 0.53
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Todd W. Bauer · 4 shared papers, 2016–2024 · strength 0.45
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. DOI 10.1186/s40425-016-0119-z↗
- Craig Lee Slingluff · 4 shared papers, 2015–2024 · strength 0.44
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. DOI 10.1186/s40425-016-0119-z↗
- Victoire Cardot‐Ruffino · 3 shared papers, 2023–2024 · strength 0.44
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Stephanie K. Dougan · 3 shared papers, 2023–2024 · strength 0.44
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Matthew H. G. Katz · 3 shared papers, 2015–2024 · strength 0.36
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combin… DOI 10.1186/2051-1426-3-s2-p167↗
- Douglas Adam Rubinson · 3 shared papers, 2021–2024 · strength 0.34
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Paper Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after ea… DOI 10.21037/jgo-21-197↗
- Paper Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-20-3141↗
- Zev A. Wainberg · 3 shared papers, 2021–2024 · strength 0.32
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- Andrew H. Ko · 3 shared papers, 2021–2024 · strength 0.32
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- Robert A. Wolff · 3 shared papers, 2021–2024 · strength 0.32
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- Eileen Mary O'Reilly · 3 shared papers, 2021–2024 · strength 0.32
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- Robert H. Vonderheide · 3 shared papers, 2021–2024 · strength 0.32
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- George Albert Fisher · 3 shared papers, 2021–2024 · strength 0.32
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- Mark H. O’Hara · 3 shared papers, 2021–2024 · strength 0.32
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- Chee‐Chee Stucky · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Rawad Elias · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Matthew J. Reilley · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Nipun B. Merchant · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Tanios Bekaii‐Saab · 2 shared papers, 2023–2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Lestat R. Ali · 2 shared papers, 2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Thomas Adam Abrams · 2 shared papers, 2024 · strength 0.30
- Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Gauri Rajani Varadhachary · 3 shared papers, 2015–2023 · strength 0.28
- Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
- Paper CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment… DOI 10.1016/s1470-2045(20)30532-5↗
- Paper A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combin… DOI 10.1186/2051-1426-3-s2-p167↗
- Harshabad Singh · 2 shared papers, 2021–2024 · strength 0.25
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Paper Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after ea… DOI 10.21037/jgo-21-197↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.